NCT06413602Active, not recruiting
The Synergistic Effects of AIH and FES in Persons With MS
Exploring the Synergistic Effects of AIH and FES in Persons With MS
Source: ClinicalTrials.gov · Last updated 23 Feb 2026
Brief summary (registry, in English)
The purpose of this study is to examine how neuromuscular electrical stimulation (NMES), may synergistically enhance corticospinal excitability in people with relapsing form multiple sclerosis (MS). This is an important intermediate step to evaluate the potential of AIH + NMES as a plasticity-priming strategy for more efficacious interventions for persons with MS. This study will measure ankle torque generation and amplitude of motor evoked potentials (MEPs) using a repeated measures study design in order to better understand the effects of AIH combined with NMES, as compared to only receiving NMES, and only receiving AIH.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 9 May 2024
- Start date
- 1 Nov 2024
- Primary completion date
- Aug 2026
- Lead sponsor
- Shirley Ryan AbilityLab
- Diseases
- Multiple sclerosis
- NCT number
- NCT06413602
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 1 Nov 2024 to the primary completion date, Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Metal in head (e.g., surgical clips, shrapnel)
- Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold such as antipsychotic drugs (chlorpromazine, clozapine) or tricyclic antidepressants
- Surgery to the head
Other illness
- Uncontrolled hypertension or hypotension (outside 140/90 and 90/60 mmHg)
- History of epilepsy or seizures
- Uncontrolled hypertension or hypotension (outside 140/90 and 90/60 mmHg)
- History of epilepsy or seizures
- Uncontrolled medical problems affecting the lungs (pulmonary diseases including chronic obstructive pulmonary disease), the heart (cardiovascular diseases) or the musculoskeletal system (orthopedic diseases)
- History of stroke
- History of seizures or epilepsy diagnosis
- Any non-MS related neurological diseases
- Illnesses that may have caused brain injury
Other
- Premorbid, ongoing major depression or psychosis, altered cognitive status
- Unexplained frequent or severe headaches
- Pregnancy in females
- Implanted devices (e.g., pacemakers, medical pumps, brain stimulators)
- Unable to participate in TMS
Who the study is looking for
- Diagnosis of relapsing form of MS
- Expanded Disability Status Scale (EDSS) score of at least 3 and no more than 6.5
- Relapse free for at least 1 year
- Age ≥18 years and ≤75 years
- No change in Dalfampridine dose at least 2 months prior to enrollment
- Age ≥18 years and ≤75 years
- Safe to participate in TMS (TMS questionnaire)
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shirley Ryan AbilityLab Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.